Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
04.08.2022 - IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in MayMr. Axel-Sven ...
Source: wallstreet-online.de